Compare Citius Pharmaceuticals Inc (CTXR) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while State Street SPDR Bloomberg High Yield Bond ETF trades at $92.83 (market cap $5.86B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is far larger — about 430.2× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 7,780,002). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and State Street SPDR Bloomberg High Yield Bond ETF for 61 Days on average.
| CTXR | JNK | |
|---|---|---|
Market Cap | $13.62M | $5.86B |
Volume | 132,438 | 7,780,002 |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $98.02 |
52-Week Low | $0.48 | $92.30 |
Typical Hold Time | 17 Days | 61 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
JNK trades at $92.73, down slightly by 0.03% with a bearish technical signal from moving averages. The ETF maintains consistent dividend payments of $0.53 per share through 2026. Recent institutional activity shows Envestnet Asset Management increased its stake by 23.3% during the latest quarter, indicating institutional confidence despite broader market volatility in high-yield bonds.
The outlook remains cautious amid rising Treasury yields and geopolitical tensions affecting bond markets. Key risks include interest rate sensitivity and economic slowdown concerns. Current technical support sits at $92 with resistance at $93, suggesting limited near-term price movement absent significant market catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
